Related Experiment Video
Updated: May 23, 2025
Isolation of Cortical Microglia with Preserved Immunophenotype and Functionality From Murine Neonates
Published on: January 30, 2014
Pro-inflammatory microglia-targeted peptide therapy ameliorates neonatal hypoxic-ischemic encephalopathy in mice
Rika Zen1, Shunichiro Tsuji1, Tomoko Maeda1
1Department of Obstetrics and Gynecology, Shiga University of Medical Science, Seta Tsukinowa-cho, Otsu, Shiga 520-2192, Japan.
Abstract:
Neonatal hypoxic-ischemic encephalopathy is aggravated by intracerebral inflammation. As pro-inflammatory microglia in the brain become activated in this condition, we aimed to establish a novel peptide therapy for neonatal hypoxic-ischemic encephalopathy by investigating the therapeutic effects of pro-inflammatory microglial depletion. MG1 homing peptide, which selectively targets and binds pro-inflammatory microglia, was conjugated with the pro-apoptotic peptide D[KLAKLAK]2 (KLA), creating MG1-KLA. After confirming that MG1-KLA selectively bound pro-inflammatory microglia and decreased cell viability by inducing apoptosis in a dose-dependent manner, the in vivo therapeutic effect of MG1-KLA was assessed following intracerebroventricular injection in hypoxic-ischemic encephalopathy model mice through histological, behavioral, and biochemical analyses. In these mice, MG1-KLA selectively bound to microglia and induced their apoptosis. Brain atrophy was significantly suppressed in the mice treated with MG1-KLA compared with non-treated mice. Additionally, motor function and locomotor hyperactivity were improved in mice treated with MG1-KLA compared with non-treated mice. Gene expression analysis further revealed that pro-inflammatory cytokine expression was downregulated in mice treated with MG1-KLA compared with non-treated mice. These findings suggest that novel MG1-KLA peptide therapy has high potential for treating neonatal patients with hypoxic-ischemic encephalopathy through the selective induction of apoptosis in pro-inflammatory microglia.
Insights
A new peptide therapy, MG1-KLA, shows promise for treating neonatal hypoxic-ischemic encephalopathy by selectively depleting pro-inflammatory microglia. This approach reduced brain atrophy and improved motor function in animal models.
Area of Science:
- Neuroscience
- Immunology
- Pharmacology
Background:
- Neonatal hypoxic-ischemic encephalopathy (HIE) involves detrimental intracerebral inflammation.
- Pro-inflammatory microglia activation exacerbates brain injury in neonatal HIE.
Purpose of the Study:
- To develop and evaluate a novel peptide therapy targeting pro-inflammatory microglia for neonatal HIE.
- To investigate the therapeutic potential of selective microglial depletion using MG1-KLA.
Main Methods:
- Conjugation of MG1 homing peptide with pro-apoptotic peptide KLA to create MG1-KLA.
- In vitro validation of MG1-KLA binding to pro-inflammatory microglia and induction of apoptosis.
- In vivo assessment of MG1-KLA efficacy in a mouse model of neonatal HIE via intracerebroventricular injection.
Main Results:
- MG1-KLA selectively targeted and induced apoptosis in pro-inflammatory microglia in vivo.
- Significant reduction in brain atrophy was observed in MG1-KLA treated mice.
- Improved motor function and reduced locomotor hyperactivity were noted in treated mice.
- Downregulation of pro-inflammatory cytokine gene expression was confirmed.
Conclusions:
- MG1-KLA peptide therapy effectively reduces brain injury and improves neurological function in a neonatal HIE model.
- Selective apoptosis induction of pro-inflammatory microglia is a viable therapeutic strategy for neonatal HIE.
- MG1-KLA demonstrates significant potential for clinical translation in treating neonatal HIE.
